ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)

BACKGROUND: TGF- signaling promotes tumor immunosuppression; TGF- inhibition in the tumor microenvironment may enhance the response to antiPD-L1 treatment. M7824 is an innovative, first-in-class, bifunctional fusion protein composed of a human antiPD-L1 IgG1 monoclonal antibody fused with two extrac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Khasraw, Mustafa, Weller, Michael, Estelles, David Lorente, Kolibaba, Kathryn, Lee, Chee, Gedye, Craig, De La Fuente, Macarena, Vicente, David, Reardon, David, Ojalvo, Laureen, Helwig, Christoph, Gourmelon, Carole, Groves, Morris
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216129/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars